Press

Glaukos Enters into Collaboration and Marketing Agreement with RadiusXR, Inc.

RadiusXR

•

17 July 2023

ALISO VIEJO, Calif.‐‐(BUSINESS WIRE)‐‐ Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a collaboration and marketing agreement with RadiusXR, Inc., whereby Glaukos will become the exclusive sales agent to market, promote and solicit orders for the RadiusXR™ wearable patient engagement and vision testing system within the United States. Radius will continue to lead development and commercialization efforts for RadiusXR.

"We are delighted to partner with Radius to strengthen commercialization efforts and expand patient access for Radius’ innovative portable vision testing system,"

- Thomas Burns

Media Inquiries

For press opportunities please email media@radiusxr.com

Media Kit

The RadiusXR platform is a novel portable vision testing and patient engagement system designed to support efficient assessment of visual function and enhance overall eye-care workflow. It combines advanced vision assessment tools, business management features, and patient education resources within a wearable spatial computing device. This comprehensive hardware and software system provides clinicians with tools to evaluate visual field performance, strengthen patient engagement, and streamline operations. It enables patients to perform self-guided vision tests with minimal supervision, improving practice efficiency and the overall patient experience.

“

Today marks a notable milestone for Radius and more importantly, for patients suffering from chronic eye diseases. Glaukos is highly trusted and respected by vision care providers, and this collaboration will provide us with the necessary resources to expedite product development, optimize benefits for eye care providers and enhance the overall quality of care and access for patients,” said Ammad Khan, Radius chief executive officer. “Through this partnership, Radius will benefit from Glaukos’ market-building expertise, leveraging its well-established sales team with extensive clinical knowledge and technical insight to commercialize and drive greater patient access for the RadiusXR technology.”

"
We are delighted to partner with Radius to strengthen commercialization efforts and expand patient access for Radius’ innovative portable vision diagnostic system," said Thomas Burns, Glaukos chairman and chief executive officer. "We believe the RadiusXR platform is a novel technology that can help drive more efficient and improved diagnosis for patients suffering from chronic eye diseases, while also creating efficiency and growth opportunities for eye care practices. This collaboration aligns with our mission to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases."

About RadiusXR

The RadiusXR platform is a revolutionary portable vision testing and patient engagement system. It combines advanced vision assessment tools, business management resources, and patient education features within a wearable spatial computing device. The RadiusExam® software and proprietary algorithms deliver reliable visual field data consistent with established clinical methods. This comprehensive hardware and software system empowers medical professionals to efficiently assess visual function, enhance patient engagement, and optimize clinical workflow. It enables patients to perform self-guided vision exams with minimal supervision, supporting the growth, flow, and efficiency of eye care practices.

About Glaukos

Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.